Effective anti-Alzheimer Aβ therapy involves depletion of specific Aβ oligomer subtypes

ABSTRACT

Background: Recent studies have implicated specific assembly subtypes of β-amyloid (Aβ) peptide, specifically soluble oligomers (soAβ) as disease-relevant structures that may underlie memory loss in Alzheimer disease. Removing existing soluble and insoluble Aβ assemblies is thought to be essential for any attempt at stabilizing brain function and slowing cognitive decline in Alzheimer disease. IV immunoglobulin (IVIg) therapies have been shown to contain naturally occurring polyclonal antibodies that recognize conformational neoepitopes of soluble or insoluble Aβ assemblies including soAβ. These naturally occurring polyclonal antibodies have been suggested to underlie the apparent clinical benefits of IVIg. However, direct evidence linking anti-Aβ antibodies to the clinical bioactivity of IVIg has been lacking.

Methods: Five-month-old female Dutch APP E693Q mice were treated for 3 months with neat IVIg or with IVIg that had been affinity-depleted over immobilized Aβ conformers in 1 of 2 assembly states. Memory was assessed in a battery of tests followed by quantification of brain soAβ levels using standard anti-soAβ antibodies.

Results: We provide evidence that NU4-type soAβ (NU4-soAβ) assemblies accumulate in the brains of Dutch APP E693Q mice and are associated with defects in memory, even in the absence of insoluble Aβ plaques. Memory benefits were associated with depletion from APP E693Q mouse brain of NU4-soAβ and A11-soAβ but not OC-type fibrillar Aβ oligomers.

Conclusions: We propose that targeting of specific soAβ assembly subtypes may be an important consideration in the therapeutic and/or prophylactic benefit of anti-Aβ antibody drugs. Neurology Neuroimmunol Neuroinflamm 2016;3:e237; doi: 10.1212/NXI.0000000000000237

GLOSSARY

Aβ = β-amyloid; AD = Alzheimer disease; EPM = elevated plus maze; FC = fear conditioning; IG = Immune Globulin; IVIg = IV immunoglobulin; nAb = naturally occurring antibody; NOR = novel object recognition; nTg = nontransgenic; oAβ = oligomeric β-amyloid; PBS = phosphate-buffered saline; SA = spontaneous alternation; soAβ = soluble oligomeric β-amyloid.

Alzheimer disease (AD), the most common form of dementia among the elderly, is attended by decades of accumulation of the neurotoxic β-amyloid (Aβ) peptide.1 Removing existing soluble and insoluble Aβ assemblies is thought to be essential for stabilizing brain function and slowing cognitive decline. While prior active or passive immunotherapies have been successful in AD mouse models, success in clinical trials has been elusive.2

IV immunoglobulin (IVIg) consists of purified plasma Ig pooled from thousands of healthy donors, is associated with reduced risk of developing AD,3 and was shown to contain naturally occurring antibody drugs.
occurring antibodies against Aβ (nAbs-Aβ).4,5 Such nAbs-Aβ appear to be decreased in patients with AD, suggesting that some component(s) of IVIg may be useful for the treatment of early sporadic or familial forms of AD,4,6 and an independent phase 3 trial of IVIg yielded benefit in patients with moderate-stage AD who carried an APOE ε4 allele.7

Immune Globulin (IG), an IVIg therapy developed by Baxter Pharmaceuticals, has shown benefit in AD models8,9 and produced cognitive benefit in early trials.10,11 IG contains nAbs that recognize conformational neoepitopes on detergent-soluble and -insoluble Aβ aggregates. However, direct evidence linking anti-Aβ antibodies to the clinical bioactivity of IG has been lacking. The aim of this study was to test the effects of neat or Aβ-affinity-depleted forms of IG on learning behaviors and pathology in Dutch APP E693Q12 transgenic mice, and to determine whether improved learning behavior(s) might be associated with the depletion of specific soluble oligomeric Aβ (soAβ) immunosubtypes.

METHODS Experimental animals. Animal procedures were conducted in accordance with the NIH Guidelines for the Care and Use of Experimental Animals and were approved by the Institutional Animal Care and Use Committee at the Icahn School of Medicine at Mount Sinai. All mice were given ad libitum access to food and water, and housed in micro-isolator cages under a 12-hour light/dark cycle. Generation of Dutch (APP E693Q) and PS1E9 transgenic mouse lines have been described previously.13 For baseline cued and contextual fear conditioning (FC) tests and anxiety-like behavior assessed in the elevated plus maze (EPM) as previously described.17,18

Behavioral testing. Mice were placed in the testing room 1 hour before testing to acclimatize to the room. All equipment was cleaned between animals. Memory was assessed in the novel object recognition (NOR), Y-maze spontaneous alternation (SA), and contextual/cued FC tests and anxiety-like behavior assessed in the elevated plus maze (EPM) as previously described.17,18

Tissue preparation. Animals were killed, perfused with ice-cold 1× PBS, and brains were hemisected. One hemisphere was postfixed in 4% paraformaldehyde, stored at 4°C, and prepared for immunohistologic analyses. The remaining hemisphere was snap frozen and stored at −80°C before biochemical analysis. Brain samples were prepared for biochemical analysis as described previously.15

Antibody-based assays. For a list of antibodies used in the current study, or for immunofluorescence and immunohistochemistry, Western blot, dot blot, and ELISA assays described here, see e-Methods at Neurology.org/nn.

Statistical analysis. Independent-samples t tests were used to determine significant differences between 2 groups. One-way analyses of variance with Bonferroni post hoc analyses were used to compare 3 or more groups. Significance for t tests and analyses of variance are reported with a p ≤ 0.05 using 2-tailed tests with an α level of 0.05. All statistical analyses were performed using GraphPad Prism 5 (GraphPad Software, La Jolla, CA).

RESULTS Impairment of hippocampus-dependent memory is evident at 6 months of age in Dutch and Dutch APP/PS1ΔE9 mice. Six-month-old nTg, Dutch APP, and Dutch APP/PS1ΔE9 mice were trained and tested on the cued and contextual FC paradigm. By comparison to their nTg littermates, both Dutch APP and Dutch APP/PS1ΔE9 mice displayed significant impairment of contextual fear memory, whereas no differences were observed among the 3 groups for cued fear memory (figure 1, A and B). No significant differences were observed between male and female mice for performance on cued or contextual FC tasks.
Impaired contextual memory is associated with levels of soluble fibrillary oligomeric Aβ assemblies

Six-month-old mice were trained and tested for contextual (A) and cued (B) fear memory. Brain lysates were analyzed for levels of soAβ (C), soluble Aβ42/40 (D), and insoluble aggregated Aβ42 (E). Using conformation-specific antibodies, levels of soluble prefibrillar (F) or fibrillar (G) oAβ were analyzed from brain lysates. (H) Brain sections were stained for soluble prefibrillar oAβ assemblies (A11) or nuclear oligomeric assemblies (M78); counterstain is DAPI. Data are representative littermates; histograms represent mean ± SEM; *p < 0.05; **p < 0.01; ***p < 0.001. Aβ = β-amyloid; Agg. = aggregated; AU = arbitrary units; DAPI = 4',6-diamidino-2-phenylindole; nTg = nontransgenic; oAβ = oligomeric β-amyloid; soAβ = soluble oligomeric β-amyloid.

(data not shown), consistent with our prior observations using the Morris water maze task12; therefore, males and females were combined for analysis. Because both contextual and cued fear memory rely on an intact amygdala,20 but only contextual memory relies additionally on an intact hippocampus, our data suggest that impaired contextual memory reflects a defect in hippocampus-dependent memory. This finding is consistent with prior studies of AD mouse models12,19,20 and patients with AD.21 No difference was observed between Dutch APP and Dutch APP/PS1ΔE9 mice for contextual memory, suggesting that the cause of cognitive defect may be common (i.e., related to APP E693Q transgene product) among the 2 mouse lines and not related to the accumulation of amyloid plaques that occurs only in Dutch/PS1ΔE9 mice.

Accumulation of soluble, but not insoluble, oligomeric Aβ assemblies is a common feature among Dutch APP and Dutch APP/PS1ΔE9 mice. Using a 7n22/7n22 duplicate-epitope sandwich immunoassay, we measured levels of total soAβ assemblies from both mouse lines. No differences were observed between Dutch APP and Dutch APP/PS1ΔE9 littermates for levels of soAβ assemblies (figure 1C). Next, we measured levels of soluble Aβ40 and Aβ42, revealing a significant difference between Dutch APP and Dutch APP/
PS1ΔE9 mice for Aβ42/Aβ40 ratio (figure 1D), which is consistent with expression of the PS1ΔE9 transgene.12,22 We also observed a nearly 10-fold-higher accumulation of detergent-insoluble aggregated Aβ42 in the brains of Dutch APP/PS1ΔE9 mice as compared to their Dutch APP littermates (figure 1E).

Based on the observation that both mouse lines accumulate the same amount of soAβ assemblies (figure 1C), we utilized conformation-specific antibodies to assess the native conformation of the soAβ assemblies. We noted a significant decrease in levels of A11-immunoreactive soluble prefibrillar Aβ assemblies among Dutch APP/PS1ΔE9 mice when compared to their Dutch APP littermates (figure 1, F and H), whereas no difference was observed between the 2 genotypes for levels of OC-immunoreactive soluble fibrillar Aβ assemblies (figure 1G).

Previously, we reported marked intraneuronal accumulation of APP/Aβ in the brains of both Dutch APP and Dutch APP/PS1ΔE9 mice.12 We further characterized this pathology, revealing subtle differences in intra- and extraneuronal pathology between the genotypes (figure 2). Whereas Dutch APP mice primarily exhibited perinuclear intracellular 4G8-immunoreactivity without plaque-like M31-immunoreactivity, Dutch APP/PS1ΔE9 mice exhibited punctate intracellular 4G8-immunoreactivity and plaque-like M31-immunoreactivity (figure 2).

We analyzed brain lysates from nTg, Dutch APP, and Dutch APP/PS1ΔE9 for markers of autophagic/lysosomal stasis including LC3, p62, α-synuclein, and APP in order to determine whether autophagic/lysosomal failure was evident and/or associated with accumulation of soAβ assemblies or insoluble Aβ42. No accumulation of soluble LC3, p62, or α-synuclein was observed by comparison to nTg controls among either Dutch APP or Dutch APP/PS1ΔE9 mice, suggesting that autophagic/lysosomal clearance may be intact at this stage of pathology (figure 3). However, we noted a significant accumulation of insoluble p62 among only Dutch APP/PS1ΔE9 mice by comparison to their nTg and Dutch APP littermates (figure 3, A and C) and this effect was also observed to precede onset of autophagic/lysosomal failure in TgCRND8 mice.19 Based on this result, it is tempting to speculate that the insoluble accumulation of Aβ42 and p62 may represent an early marker of toxicity to the autophagic/lysosomal pathway; however, further aging studies with these mouse lines will be necessary to determine whether autophagic/lysosomal failure occurs at any age.

Treatment of Dutch mice with IG rescued learning behavior. Next, we sought to determine whether antibodies against various forms of soluble or insoluble Aβ assemblies may be responsible for the benefit provided by IG therapy. We previously reported deficits on hippocampus-dependent memory in the Morris water maze task and FC in the Dutch APP mouse line.12,23 Here, we chose a battery of tasks that target...
both hippocampus-dependent memory as well as the entorhinal cortex and amygdala to assess complete memory function; these include FC,17,23 NOR,17,23 and Y-maze SA (previously untested), or anxiety-like behaviors using the EPM (previously reported17,23). Three-month treatment of Dutch APP mice by once-weekly subcutaneous injection of neat IG prevented onset of NOR (figure 4A), SA (figure 4B), and FC (figure 4C) deficits, without affecting anxiety-like behavior in the EPM (figure 4D) in female Dutch APP mice. This behavioral protection was completely abrogated by treatment with either saline or fibrillar \( \alpha \beta \)-affinity-depleted or total \( \alpha \beta \)-affinity-depleted IG. However, a statistically significant benefit in learning behavior tasks (e.g., NOR) was observed among Dutch APP mice treated with oligomer \( \alpha \beta \)-affinity-depleted IG (figure 4A).

Treatment of mice with neat IG did not affect brain levels of \( \alpha \beta_{40} \) (figure 5, A–D) or \( \alpha \beta_{42} \) (figure 5, E–H), or its ratio (figure 5, I–L), but rather reduced brain levels of both toxic prefibrillar A11-immunoreactive so\( \alpha \beta \) (figure 5M) and NU-4-immunoreactive assemblies (figure 5N) in Dutch APP mice. Levels of OC-immunoreactive soluble fibrillar oligomers were not affected following treatment with neat IG in Dutch mice (figure 5O). Treatment of mice with fibrillar \( \alpha \beta \)-affinity-depleted IG apparently reduced brain levels of NU-4-immunoreactive (figure 5N) but not A11-immunoreactive (figure 5M) so\( \alpha \beta \) assemblies in Dutch APP mice. Thus, neat IG treatment was associated with clinical benefit and reduction of 2 immunosubtypes of so\( \alpha \beta \) assemblies (i.e., both A11-type and NU-4-type oligomers). Among 3 immunoaffinity-depleted IG preparations, only one was clinically effective, and, unexpectedly, that bioactive fraction was the fibrillar \( \alpha \beta \)-affinity-depleted IG that was associated with reduction in the content of NU-4-type so\( \alpha \beta \) assemblies. We cannot determine whether reduction in the content of A11-type so\( \alpha \beta \) assemblies might also be associated with clinical benefit. The relevance of this point is discussed in detail below.

**DISCUSSION** The current study indicates the utility of rodent models to study multiple stages of AD-related pathology, the relationship of \( \alpha \beta \) pathology to cognitive status, and the ability to separate canonical \( \alpha \beta \) plaque pathology from underlying toxic mechanisms. Here, we describe a hippocampus-dependent contextual fear memory deficit at 6 months of age in Dutch APP and Dutch APP/PS1\( \Delta E9 \) mice, and the accumulation of cognitive deficit–associated so\( \alpha \beta \) assemblies that are common to both lines. Of note, prior studies indicate that A11-immunoreactive prefibrillar so\( \alpha \beta \) assemblies are associated with conversion from soluble low-n multimers to insoluble fibrillar assemblies, whereas OC-immunoreactive soluble fibrillar so\( \alpha \beta \) assemblies do not form fibrils and, rather, seed formation of more soluble fibrillar so\( \alpha \beta \) assemblies.24 Moreover, levels of so\( \alpha \beta \) assemblies were recently found to be predictive of cognitive status at death among patients with AD,25 validating our findings (as discussed above) and the utility of these mouse models of AD. Here, we noted a significant decrease in A11-immunoreactive so\( \alpha \beta \) assemblies among Dutch APP/PS1\( \Delta E9 \) mice as
compared to their Dutch APP littermates (figure 1, F–H; table). Our conclusions are supported by recent work by Liu et al.  

Figure 4  Prevention of onset of behavioral deficits following 3-month treatment of Baxter IG in Dutch APP E693Q transgenic mice

Five-month-old female Dutch APP E693Q transgenic mice were given weekly subcutaneous injections of either saline (n = 11) or 2 g/kg neat Baxter IG (n = 12), 2 g/kg IG depleted of anti-fibril Aβ antibodies (fibril Aβ-affinity-depleted IG; n = 11), 2 g/kg IG depleted of anti-oligomer Aβ antibodies (oligomer Aβ-affinity-depleted IG; n = 11), or 2 g/kg IG depleted of both anti-oligomer and anti-fibril Aβ antibodies (Aβ-affinity-depleted IG; n = 11) for 3 months. Unlike treatment of saline, fibril Aβ-affinity-depleted IG and Aβ-affinity-depleted IG, treatment of IG prevented onset of behavioral deficits in novel object recognition (A), Y-maze spontaneous alternation (B), and contextual/cued fear conditioning (C) without affecting anxiety-like behavior in the elevated plus maze (D) in Dutch APP E693Q transgenic mice. Treatment of oligomer Aβ-affinity-depleted IG prevented onset of behavioral deficit in novel object recognition (A) in Dutch APP E693Q transgenic mice. *p < 0.05; **p < 0.01; 1-way analysis of variance with Bonferroni post hoc analyses. Data expressed as mean ± SEM. Aβ = β-amyloid; IG = Immune Globulin.

Our group recently performed an integrative genomic analysis of the transcriptomes from human AD brain tissue or 2 independent mouse lines (including the Dutch APP mouse line) to identify altered molecules and pathways between wild-type and transgenic mice, and human patients with AD. These studies revealed consistent alterations in APP/Aβ metabolism, epigenetic control of neurogenesis, cytoskeletal organization, and extracellular matrix regulation. Comparison of these transcriptomic results with human AD postmortem gene expression data indicated significant similarities in pathway alterations between mouse models and patients with AD. In addition, it has been reported that changes in neuroinflammation-related gene regulation at early stages of AD was not related to neurofibrillary tangles, Aβ plaque burden, total Aβ_{40} or Aβ_{42}, or membrane-bound
fibrillar Aβ, but rather to increased levels of soAβ.29 Taken together, these studies suggest that soAβ assemblies represent a critical driver of early-stage disease processes, leading to cognitive and cellular dysfunction observed at later stages of disease.

IVIg formulations have been previously assessed in other mouse models of AD, demonstrating that peripheral administration of IVIg crossed the blood–brain barrier and binding of Aβ deposits in APP/PS-1 mice. In ex vivo APP/PS-1 brain sections, IVIg enhanced microglial-mediated Aβ clearance and depletion of nAbs-Aβ in IVIg significantly reduced clearance.8 Treatment of TgCRND8 mice with nAbs-Aβs isolated from IVIg reduced plaque load in mice treated at 3 months of age but not those treated later during disease progression, at 12 months of age.30 When memory was assessed in Tg2576 mice, nAbs-Aβ treatment improved object recognition.30 In contrast, when APP/PS1ΔE9 mice were treated with IVIg for 3 or 8 months, no evidence of reduced Aβ was reported.9 Instead, increased monomeric Aβ40 and Aβ42 levels, enhancement of neurogenesis, suppression of proinflammatory cytokine gene expression, and evidence of modulation of microglial activation was observed in mice treated for 8 months.9 More recently, another study in Tg2576 mice saw an improvement in memory and synaptic plasticity following IVIg treatment that was not
results suggest that IG may contain NU4-like and/or A11-like antibodies that contribute to therapeutic benefit in the Dutch APP E693Q mouse model.

Antibodies used in the current study are summarized to reflect known specificity, preparation, and clonality. IG antibodies were administered to Dutch APP E693Q mice before behavioral testing and biochemical studies. Soluble Aβ assemblies were recognized by NU-4 and A11, were reduced following treatment with neat IG, but neither oligomeric-Aβ-depleted IG nor Aβ-depleted IG. NU-4 epitopes were also reduced in the brains of mice treated with fibril-Aβ-depleted IG, suggesting that the relevant soluble oligomeric Aβ assemblies providing cognitive benefit from IG are not fibrils or fibril-like in structure. Our results suggest that IG may contain NU4-like and/or A11-like antibodies that contribute to therapeutic benefit in the Dutch APP E693Q mouse model. IG contains antibodies against both monomeric and soAβ. In vitro studies in N2a neuroblastoma cells have revealed that IVIg can disaggregate Aβ fibrils and promote Aβ removal while preventing neurotoxicity-associated soAβ assemblies. Similarly, in cultured primary mouse hippocampal neurons, treatment with IVIg has been shown to reduce Aβ fibril formation and reduce Aβ neurotoxicity. Many studies, including ours, revealed no detectable reduction in monomeric Aβ. When IVIg was assessed in the 3xTgAD model of AD, an improvement in NOR, reduced immunologic CD4/CD8 blood ratio, reduced interleukin (IL)-5/IL-10 ratio in the cortex together with limited effects on tau but reduced Aβ42/40 ratio and levels of soluble 56-kDA Aβ oligomers were reported. Our study is the first to focus on oligomer immunosubtypes post IVIg treatment. In the present study, IG protection was not associated with altered levels of monomeric Aβ40 and Aβ42 levels but rather with decreased levels of some but not all immunosubtypes of soluble prefibrillar oligomeric Aβ assemblies. A11-immunosubtype and/or NU4-immunosubtype soAβ assemblies appear to be the key conformer(s) driving memory failure. This study suggests that IG may contain A11-like and NU-4-like antibodies that confer some protection in the Dutch APP mouse line. An unexpected result of this study is the improvement in NOR in the oligomer Aβ-affinity-depleted IG-treated mice with no change in Aβ biochemistry. One explanation for this result is that the oligomer preparation used for fibrillar and oligomer Aβ affinity depletion of IG may not contain a complete and comprehensive representation of the structurally diverse spectrum of soluble Aβ assemblies. In other words, these 2 affinity-depleted IG fractions designated “oligomeric” or “fibrillar” may represent an oversimplified binary classification. Another possibility is that the nAbs may contain catalytic antibodies that induce changes in the conformations of the soAβ assemblies as part of their therapeutic bioactivity. “Chaperone-like” activity has been reported for other antibodies such that the antibodies induce changes in the conformation of soAβ assemblies as part of their therapeutic action and/or as a biochemical reaction in IG-treated brain homogenates during assays. We are currently characterizing the chaperone content of our IG fractions in order to assess this possibility properly.

Baxter IG has been proposed as a potential treatment for AD, especially at moderate stage and in carriers of APOE e4 alleles. IG contains natural human polyclonal IgG antibodies that recognize conformational neoepitopes expressed on soluble and insoluble Aβ assemblies. The current study demonstrates for the first time that 3 months of neat IG treatment of Dutch APP transgenic Aβ-oligomer-forming mice is associated with prevention of memory deficits in NOR, SA, and FC that is abrogated by affinity depletion of IG using certain conformers of soluble Aβ assemblies. These principles might well be kept in mind during the continued development and optimization of active and passive anti-Aβ immunotherapies and during the continued early-stage work on creating therapeutic chaperones that have the capacity to stabilize soAβ assemblies in nontoxic conformations.
AUTHOR CONTRIBUTIONS

STUDY FUNDING
This work was supported in part by a grant from Baxter Pharmaceuticals, Inc. J.W.S. is supported by NIH grant K12 GM068524. This work was additionally supported by NIH grants P50 AG05138 (to Mary Sano; S.G.), U01 AG046710 (S.G., M.E.), R34 AG049649 (S.G.), R01 NS075685 (S.G.), R01 MH065365 (C.M.A.), R21 AT005510 (S.G.), RF1 AG042965 (S.G.), VA MERIT Review Grant 101 RX006084 (S.G.), the Cure Alzheimer’s Fund (S.G.), and gifts from the Louis B. Mayer Foundation, the Sarah and Gideon Garmer Trust, the Rudin Foundation, and the Werber Family Foundation (all to S.G.).

DISCLOSURE
E. Knight, S.H. Kim, and J. Kotrutzit report no disclosures. A. Hatami is an associate editor for Journal of Alzheimer’s Disease, received research support from NIH, Cure Alzheimer’s Fund. R. Alby and A. Suzuki report no disclosures. A. Lublin has been employed by Sanofi Genzyme, received research support from University of California, Riverside, holds stock or stock options in Geron and Ionis. C. Alberini is on the editorial board for Neural Plasticity, Neurobiology of Learning and Memory, was on the editorial board for Cell Science, is an associate editor for Frontiers in Neuroscience, received research support from NIH. W.L. Klein served on the scientific advisory board for Acumen Pharmaceuticals, received research support from NIH, Baxter-NU Alliance, NUCATS/Northwestern. P. Szabo reports no disclosures. N. Relkin served on the scientific advisory board for Anavex, Herbal Science Group, Eisai, was an associate editor for Neurology Alert, has patents pending for Multiplexed CSF markers for Alzheimer’s disease, Diffusion tensor histogram analysis for diagnosis of hydrocephalus: an analytic method for identifying a DTI pattern associated with normal pressure hydrocephalus, Volumetric MRI for predicting response to IVlg treatment of Alzheimer’s disease, Cytokine analysis for predicting response to IVlg treatment of Alzheimer’s disease, Systems and methods for automating the retrieval of portioned search results, receives royalties from UpToDate, has consulted for Aisai, Forest, Hydrocephalus Association. M. Ehrlich is on the editorial board for ASN Neuro, received research support from NIH, NYSSTEM. C. Globe served on the editorial board for Journal of Molecular Neurodegeneration, has patents and pending patents for immunotherapy and immunodiagnoses for AD, consults relating to intellectual property, receives license fee and royalty payments for antibodies for research purposes only and patent issues, received research support from NIH, Cure Alzheimer’s Fund, was involved in legal proceedings for Sidney LLP. S. Gandy is an associate editor for ADAD, Molecular Neurodegeneration, is a consulting editor for FCI, received research support from Avadl Lilly, Constellation Wines. J. Steele is a scientific advisory board member for OrPh Therapeutics Inc., was editor-in-chief and consulting editor for Journal of Postdoctoral Research, has a pending patent for Mitoprotection for treatment of lysosomal storage diseases, consulted for Amicus Therapeutics, received research support from CurePSP, DPD Deficiency Foundation, is a co-founder and on the board of directors for OrPh Therapeutics Inc., holds stock or stock options in Amicus Therapeutics, GlaxoSmithKline. Go to Neurology.org/an for full disclosure forms.

POTENTIAL CONFLICT OF INTEREST STATEMENT
J.W.S. is a cofounder, shareholder, and member of the board of directors and scientific advisory board of OrPh Therapeutics Inc. (Carlsbad, CA). Within the past 5 years, S.G. has held research grants from Amicus Therapeutics. S.G. is also a member of the Data and Safety Monitoring Board for the Pfizer-Janssen Alzheimer’s Immunotherapy Alliance.

Received December 18, 2015; Accepted in final form April 4, 2016.

REFERENCES


34. St-Amour I, Pare I, Tremblay C, Coulombe K, Bazin R, Calon F. IVIg protects the 3xTg-AD mouse model of Alzheimer’s disease from memory deficit and Abeta pathology. J Neuroinflammation 2014;11:54.


Effective anti-Alzheimer Aβ therapy involves depletion of specific Aβ oligomer subtypes
Elysse M. Knight, Soong Ho Kim, Jessica C. Kottwitz, et al.
Neurol Neuroimmunol Neuroinflamm 2016;3;
DOI 10.1212/NXI.0000000000000237

This information is current as of May 10, 2016

<table>
<thead>
<tr>
<th>Updated Information &amp; Services</th>
<th>including high resolution figures, can be found at: <a href="http://nn.neurology.org/content/3/3/e237.full.html">http://nn.neurology.org/content/3/3/e237.full.html</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Supplementary Material</td>
<td>Supplementary material can be found at: <a href="http://nn.neurology.org/content/suppl/2016/05/10/3.3.e237.DC1">http://nn.neurology.org/content/suppl/2016/05/10/3.3.e237.DC1</a></td>
</tr>
<tr>
<td>References</td>
<td>This article cites 39 articles, 8 of which you can access for free at: <a href="http://nn.neurology.org/content/3/3/e237.full.html##ref-list-1">http://nn.neurology.org/content/3/3/e237.full.html##ref-list-1</a></td>
</tr>
<tr>
<td>Citations</td>
<td>This article has been cited by 1 HighWire-hosted articles: <a href="http://nn.neurology.org/content/3/3/e237.full.html##otherarticles">http://nn.neurology.org/content/3/3/e237.full.html##otherarticles</a></td>
</tr>
<tr>
<td>Subspecialty Collections</td>
<td>This article, along with others on similar topics, appears in the following collection(s): Alzheimer's disease <a href="http://nn.neurology.org/cgi/collection/alzheimers_disease">http://nn.neurology.org/cgi/collection/alzheimers_disease</a></td>
</tr>
<tr>
<td>Permissions &amp; Licensing</td>
<td>Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://nn.neurology.org/misc/about.xhtml#permissions">http://nn.neurology.org/misc/about.xhtml#permissions</a></td>
</tr>
<tr>
<td>Reprints</td>
<td>Information about ordering reprints can be found online: <a href="http://nn.neurology.org/misc/addir.xhtml#reprintsus">http://nn.neurology.org/misc/addir.xhtml#reprintsus</a></td>
</tr>
</tbody>
</table>